This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in ...

Shares of AstraZeneca PLC ($GB:AZN) fell by over 3% as of writing after the pharma company released an unsatisfactory outcome ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...

Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ...

Daiichi Sankyo Co. shares drop as much as 10.4% on Tuesday, the most since Aug. 5, after its lung cancer drug with ...

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...

The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.

AstraZeneca's Dato-DXd faces challenges in overall survival data but holds potential for approval with promising PFS benefits ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.